FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Purpose: To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma. Methods: Patients with stage IV metastatic melanoma and BRAF V600E mutations (n = 11, 31–68 years of age) were included. Treatment was with oral dabrafenib, 150 mg bid, trametinib, 2 mg/day, and HCQ, 400 mg to 600 mg bid. An ophthalmic examination, spectral domain optical coherence tomography, near-infrared and short-wavelength fundus autofluorescence, and static perimetry were performed at baseline, 1 month, and q/6 months after treatment. Results: There were no clinically significant ocular events; there was no ocular inflammation. The only medication-related change was a separation of the photoreceptor outer segment tip from the apical retinal pigment epithelium that could be traced from the fovea to the perifoveal retina noted in 9/11 (82%) of the patients. There were no changes in retinal pigment epithelium melanization or lipofuscin content by near-infrared fundus autofluorescence and short-wavelength fundus autofluorescence, respectively. There were no inner retinal or outer nuclear layer changes. Visual acuities and sensitivities were unchanged. Conclusion: BRAFi (trametinib) + MEKi (dabrafenib) + HCQ causes very frequent, subclinical separation of the photoreceptor outer segment from the apical retinal pigment epithelium without inner retinal changes or signs of inflammation. The changes suggest interference with the maintenance of the outer retinal barrier and/or phagocytic/pump functions of the retinal pigment epithelium by effective MEK inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One report on a combination treatment with Dabrafenib + Trametinib for advanced melanoma documented very frequent subclinical separation of the photoreceptor outer segment from the apical retinal pigment epithelium without inner retinal changes or signs of inflammation [ 217 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [217]
In the citing paper
“The clinical picture suggests that effective MEK inhibition interferes with the maintenance of the outer retinal barrier and/or the phagocytic/pump functions of the RPE [ 217 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [217]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
The Role of Autophagy in Cancer: Therapeutic Implications
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0047 · Cited by 1,215
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)
Marmor, M. F., Kellner, U., Lai, T. Y. Y., Melles, R. B., & Mieler, W. F. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.058 · Cited by 1,164
Cited by
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Molecular Pathways and Mechanisms of BRAF in Cancer Therapy
Poulikakos, P. I., Sullivan, R. J., & Yaeger, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2138 · Cited by 145
Mehnert, J. M., Mitchell, T. C., Huang, A. C. C., Alemán, T. S., Kim, B. J., Schuchter, L. M., Linette, G. P., Karakousis, G. C., Mitnick, S., Giles, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3382 · Cited by 70
“Ophthalmologic exams included multimodal retinal imaging with spectral domain optical coherence tomography (SD-OCT), fundus autofluorescence with shortwavelength (SW), near-infrared (NIR) excitation lights, and visual fields using Humphrey Field Analyzer and a 10–2 protocol (18).”
MethodSelf-citation
Metadata
- Authors
- Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., Mitnick, S., Huang, A., Nichols, C. W., Amaravadi, R. K., Kim, B. J., & Aleman, T. S.
- Affiliations
- Department of Ophthalmology, Scheie Eye Institute at the Perelman Center for Advanced Medicine, the
- Abramson Cancer Center (US)
- Corresponding author
- Nti, Akosua A.
- Serrano, Leona W.
- Sandhu, Harpal S.
- Uyhazi, Katherine E.
- Edelstein, Ilaina D.
- Zhou, Elaine J.
- Bowman, Scott
- Song, Delu
- Nichols, Charles W.
- Kim, Benjamin J.
- ORCID
- Venue
- Retina
- Published
- 2019-03
- Volume
- 39
- Issue
- 3
- Pages
- 502-513
- ISSN
- 0275-004X (ISSN-L)
- PMC
- PMC6039280
- OpenAlex
- W2783517192
- Cited by
- 31
- References
- 90
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 1
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Heidelberg Engineering
- National Eye Institute (K12EY015398, P30EY001583)
- National Cancer Institute (P01CA114046, P50CA093372, R01CA198015, P50CA174523)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular and Laser Science Research
- Keywords
- BRAF V600E melanoma, metastatic melanoma, dabrafenib, trametinib, hydroxychloroquine, ocular toxicity, photoreceptor outer segments, retinal pigment epithelium, fundus autofluorescence, optical coherence tomography
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Enzyme Inhibitors, Female, Humans, Hydroxychloroquine, Imidazoles, Macula Lutea, Male, Melanoma, Middle Aged, Oximes, Photoreceptor Cells, Pyridones, Pyrimidinones, Retinal Diseases, Protein Kinase Inhibitors, MAP Kinase Kinase 1, Proto-Oncogene Proteins B-raf, Retinal Pigment Epithelium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. https://app.cochat.ai/papers/10.1097/iae.0000000000002027
- The paper
- Nti, A. A., Serrano, L. W., Sandhu, H. S., Uyhazi, K. E., Edelstein, I. D., Zhou, E. J., Bowman, S., Song, D., Gangadhar, T. C., Schuchter, L. M., Mitnick, S., Huang, A., Nichols, C. W., Amaravadi, R. K., Kim, B. J., & Aleman, T. S. (2019). FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina. https://doi.org/10.1097/iae.0000000000002027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.